Neuphoria TherapeuticsNEUP -4.52%29 Buyback Yield % is -98.08 as of Jul. 04, 2026. GuruFocus rates NEUP with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 744 Biotechnology companies, Neuphoria Therapeutics ranks worse than 90.59% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Neuphoria Therapeutics Buyback Yield % Related Terms
Neuphoria Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Neuphoria Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NEUP vs PLRZ, SKYE, IGC: Buyback Yield % Comparison
For the Biotechnology subindustry, Neuphoria Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuphoria Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Neuphoria Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuphoria Therapeutics (NEUP) has a Buyback Yield % of -98.08 as of Jul. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neuphoria Therapeutics and its competitors. According to the industry distribution chart, Neuphoria Therapeutics ranks #674 out of 744 companies in the Biotechnology industry, placing it in the top 90.6%.
Is Neuphoria Therapeutics' Buyback Yield % too high?
Neuphoria Therapeutics' current Buyback Yield % is -98.08. Based on the distribution chart, Neuphoria Therapeutics ranks #674 out of 744 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neuphoria Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Buyback Yield % compare to PLRZ and SKYE?
According to the Biotechnology industry distribution chart, Neuphoria Therapeutics ranks #674 out of 744 companies for Buyback Yield %. This places Neuphoria Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neuphoria Therapeutics and its competitors. Neuphoria Therapeutics's current Buyback Yield % is -98.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Buyback Yield % of -98.08. The current Buyback Yield % is -98.08. Neuphoria Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Buyback Yield % is -98.08 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
29GF Score
Get the complete analysis for NEUP
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEUP has been successfully added to your 
